Synthesis and evaluation of substituted naphthalimide nitrogen mustards as rationally designed anticancer compounds

Acta Poloniae Pharmaceutica - Drug Research

Volumn 60, Issue 4, 2003, Pages 285-291

  Pain, A ^a   Samantha, S ^a   Dutta, S ^a   Saxena, A K ^b   Shanmugavel, M ^b   Kampasi, H ^b   Quazi, G N ^b   Sanyal, U ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Anticancer activity; New anticancer agent; Screening; Synthesis

Indexed keywords

AMIDE; AMONAFIDE; ANTINEOPLASTIC AGENT; BROMONAPNUSTINE; CHLORMETHINE DERIVATIVE; CHLORONAPMUSTINE; CYCLOPHOSPHAMIDE; DNA; FLUOROURACIL; IMIDE; MITONAFIDE; RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CONTROLLED STUDY; DNA ALKYLATION; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; EHRLICH ASCITES TUMOR; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; REPRODUCIBILITY; RNA SYNTHESIS; SARCOMA; SURVIVAL TIME; TUMOR CELL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; DNA, NEOPLASM; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDES; NITROGEN MUSTARD COMPOUNDS; RNA, NEOPLASM; SPECTROPHOTOMETRY, INFRARED; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 0142105993     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Tew K.D., Colvin O.M., Chabner B.A.: in Cancer Chemotherapy and Biotherapy - Principles and Practice. Chabner B.A. and Longo D.L., Ed., p. 373, Lippincot Williams & Wilkins, Philadelphia, USA, 2001 and the references cited therein.
2. Tercel M., Lee A.E., Hogg A., Anderson R.F., Lee H.H., Siim B.G., Denny W.A., Wilson W.R.: J. Med. Chem. 44, 3511 (2001) and the references cited therein.
3. Brana M.F., Sanz A.M., Castellano J.M., Roldan C.M., Roldan C.M.: Eur. J. Med. Chem. 16, 207 (1981).
4. Brana M.F., Castellano J.M., Roldan C.M., Santos A., Vazquez D., Jimenez A.: Cancer Chemother. Pharmacol. 4, 66 (1980).
5. Rosell R., Carles J., Abad A., Ribelles N., Barnadas A., Benavides A., Martin M.: Invest. New Drugs 10, 171 (1992).
6. Samanta S., Pain A., Dutta S., Sanyal U.: Acta Poloniae Pharmaceutica - Drug Research 58, 351 (2001).
7. Grayshan P.H., Khandhim A.M., Peters A.T.: J. Heterocyclic Chem. 11, 33 (1974).
8. Papenfuhs T.: German Patent 2, 423, 548 (Nov. 1975) through Chem. Abs. 84, P61200w.
9. Jianhua Su., Yanta T., Kongchang C., He T.: Huadong Ligong Daxue Huebao 22, 422 (1996).
10. Geran R.I., Greenberg N.H., Mac Donald M.M., Schumacher A.M., Abbott B.J.: Cancer Chemother. Rep., Part 3, 3, 1 (1972).
11. Panda C.K., Chowdhury K., Sanyal U., Chakraborti S.K.: Chemotherapy 35, 174 (1989).
12. Dasgupta P.S., Lahiri T.: J. Cancer Res. Clin. Oncol. 113, 363 (1987).
13. Skehan P., Storeng R., Scudiero D., Monks A., Mcmahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R.: J. Natl. Cancer Inst. 82, 1107 (1990).
14. Wheeler G.P., Chumley S.: J. Med. Chem. 10, 259 (1967).
15. 15 Colvin M.: in Clinical Pharmacology of antineoplastic drugs. Pindo H.M., Ed., p. 245 Elsevier, Amsterdam, 1978.